OBJECTIVE: To evaluate the long-term outcomes of sentinel lymph node biopsy (SLNB) for head and neck cutaneous melanoma (HNCM). STUDY DESIGN: Retrospective cohort study. SETTING: Tertiary academic medical center. SUBJECTS AND METHODS: Longitudinal review of a 356-patient cohort with HNCM undergoing SLNB from 1997 to 2007. RESULTS: Descriptive characteristics included the following: age, 53.5 ± 19 years (mean ± SD); sex, 26.8% female; median follow-up, 4.9 years; and Breslow depth, 2.52 ± 1.87 mm. Overall, 75 (21.1%) patients had a positive SLNB. Among patients undergoing completion lymph node dissection following positive SLNB, 20 (27.4%) had at least 1 additional positive nonsentinel lymph node. Eighteen patients with local control and negative SLNB developed regional disease, indicating a false omission rate of 6.4%, including 10 recurrences in previously unsampled basins. Ten-year overall survival (OS) and melanoma-specific survival (MSS) were significantly greater in the negative sentinel lymph node (SLN) cohort (OS, 61% [95% CI, 0.549-0.677]; MSS, 81.9% [95% CI, 0.769-0.873]) than the positive SLN cohort (OS, 31% [95% CI, 0.162-0.677]; MSS, 60.3% [95% CI, 0.464-0.785]) and positive SLN/positive nonsentinel lymph node cohort (OS, 8.4% [95% CI, 0.015-0.474]; MSS, 9.6% [95% CI, 0.017-0.536]). OS was significantly associated with SLN positivity (hazard ratio [HR], 2.39; P < .01), immunosuppression (HR, 2.37; P < .01), angiolymphatic invasion (HR, 1.91; P < .01), and ulceration (HR, 1.86; P < .01). SLN positivity (HR, 3.13; P < .01), angiolymphatic invasion (HR, 3.19; P < .01), and number of mitoses (P = .0002) were significantly associated with MSS. Immunosuppression (HR, 3.01; P < .01) and SLN status (HR, 2.84; P < .01) were associated with recurrence-free survival, and immunosuppression was the only factor significantly associated with regional recurrence (HR, 6.59; P < .01). CONCLUSIONS: Long-term follow up indicates that SLNB showcases durable accuracy, safety, and prognostic importance for cutaneous HNCM.
OBJECTIVE: To evaluate the long-term outcomes of sentinel lymph node biopsy (SLNB) for head and neck cutaneous melanoma (HNCM). STUDY DESIGN: Retrospective cohort study. SETTING: Tertiary academic medical center. SUBJECTS AND METHODS: Longitudinal review of a 356-patient cohort with HNCM undergoing SLNB from 1997 to 2007. RESULTS: Descriptive characteristics included the following: age, 53.5 ± 19 years (mean ± SD); sex, 26.8% female; median follow-up, 4.9 years; and Breslow depth, 2.52 ± 1.87 mm. Overall, 75 (21.1%) patients had a positive SLNB. Among patients undergoing completion lymph node dissection following positive SLNB, 20 (27.4%) had at least 1 additional positive nonsentinel lymph node. Eighteen patients with local control and negative SLNB developed regional disease, indicating a false omission rate of 6.4%, including 10 recurrences in previously unsampled basins. Ten-year overall survival (OS) and melanoma-specific survival (MSS) were significantly greater in the negative sentinel lymph node (SLN) cohort (OS, 61% [95% CI, 0.549-0.677]; MSS, 81.9% [95% CI, 0.769-0.873]) than the positive SLN cohort (OS, 31% [95% CI, 0.162-0.677]; MSS, 60.3% [95% CI, 0.464-0.785]) and positive SLN/positive nonsentinel lymph node cohort (OS, 8.4% [95% CI, 0.015-0.474]; MSS, 9.6% [95% CI, 0.017-0.536]). OS was significantly associated with SLN positivity (hazard ratio [HR], 2.39; P < .01), immunosuppression (HR, 2.37; P < .01), angiolymphatic invasion (HR, 1.91; P < .01), and ulceration (HR, 1.86; P < .01). SLN positivity (HR, 3.13; P < .01), angiolymphatic invasion (HR, 3.19; P < .01), and number of mitoses (P = .0002) were significantly associated with MSS. Immunosuppression (HR, 3.01; P < .01) and SLN status (HR, 2.84; P < .01) were associated with recurrence-free survival, and immunosuppression was the only factor significantly associated with regional recurrence (HR, 6.59; P < .01). CONCLUSIONS: Long-term follow up indicates that SLNB showcases durable accuracy, safety, and prognostic importance for cutaneous HNCM.
Entities:
Keywords:
cutaneous; false omission; head and neck; melanoma; otolaryngology; sentinel lymph node biopsy
Authors: John E Hanks; Pratyusha Yalamanchi; Kevin J Kovatch; S Ahmed Ali; Joshua D Smith; Alison B Durham; Carol R Bradford; Kelly M Malloy; Scott A McLean Journal: Laryngoscope Date: 2019-08-23 Impact factor: 3.325
Authors: Michael Reintgen; Lauren Murray; Kurt Akman; Rosemary Giuliano; Alyson Lozicki; Steve Shivers; Douglas Reintgen Journal: Ann Surg Oncol Date: 2012-10-05 Impact factor: 5.344
Authors: Grant W Carlson; Douglas R Murray; Robert H Lyles; Andrea Hestley; Cynthia Cohen Journal: Plast Reconstr Surg Date: 2005-03 Impact factor: 4.730
Authors: C M Balch; A C Buzaid; S J Soong; M B Atkins; N Cascinelli; D G Coit; I D Fleming; J E Gershenwald; A Houghton; J M Kirkwood; K M McMasters; M F Mihm; D L Morton; D S Reintgen; M I Ross; A Sober; J A Thompson; J F Thompson Journal: J Clin Oncol Date: 2001-08-15 Impact factor: 44.544
Authors: Michael S Sabel; Kent Griffith; Vernon K Sondak; Lori Lowe; Jennifer L Schwartz; Vincent M Cimmino; Alfred E Chang; Riley S Rees; Carol R Bradford; Timothy M Johnson Journal: J Am Coll Surg Date: 2005-07 Impact factor: 6.113
Authors: Donald L Morton; John F Thompson; Alistair J Cochran; Nicola Mozzillo; Robert Elashoff; Richard Essner; Omgo E Nieweg; Daniel F Roses; Harald J Hoekstra; Constantine P Karakousis; Douglas S Reintgen; Brendon J Coventry; Edwin C Glass; He-Jing Wang Journal: N Engl J Med Date: 2006-09-28 Impact factor: 91.245
Authors: Stanley P L Leong; Mohammed Kashani-Sabet; Renee A Desmond; Robert P Kim; Dennis H Nguyen; Kensho Iwanaga; Patrick A Treseler; Robert E Allen; Eugene T Morita; Yuting Zhang; Richard W Sagebiel; Seng-Jaw Soong Journal: World J Surg Date: 2005-06 Impact factor: 3.352
Authors: Matthew P Doepker; Maki Yamamoto; Matthew A Applebaum; Nupur U Patel; M Jaime Montilla-Soler; Amod A Sarnaik; C Wayne Cruse; Vernon K Sondak; Jonathan S Zager Journal: Ann Surg Oncol Date: 2016-09-22 Impact factor: 5.344
Authors: Timothy R Fincher; Todd M McCarty; Tammy L Fisher; John T Preskitt; Zelig H Lieberman; Jeffrey F Stephens; John C O'Brien; Joseph A Kuhn Journal: Am J Surg Date: 2003-12 Impact factor: 2.565
Authors: Kirsten M Baecher; Michael K Turgeon; Caroline R Medin; Geetha Mahendran; Terrill M Flakes; Keith A Delman; Michael C Lowe Journal: Am Surg Date: 2021-11-11 Impact factor: 0.688